Fetal Growth Restriction a Case Control Study

Maternal Serum Progesterone And Placental Heme Oxgenase-1 Expression In Early Onset Idiopathic Fetal Growth Restriction: A Case Control Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07025031

Enrollment

Registered

2025-06-17

Start date

2025-07-01

Completion date

2027-04-01

Last updated

2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Fetal Growth Restriction

Keywords

progesterone, Heme Oxygenase-1, Idiopathic fetal growth restriction

Brief summary

The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.

Detailed description

The study aims to investigate the relationship between maternal serum level of progesterone, immune-expression of HMOX-1 a placental angiogenesis marker with idiopathic fetal growth restriction.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* singleton * dated pregnancy

Exclusion criteria

* fetus with structural or chromosomal anomaly * receive treatments such as aspirin, progestogen, low molecular weight heparin * has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes * smoking * suspected intrauterine infection

Design outcomes

Primary

Measure	Time frame	Description
Maternal serum level of progesterone	At the point of recruitment from 24 until 32 weeks gestation.	Maternal blood will be withdrawn and serum isolated. Measurement of progesterone level will be performed from the serum sample using ELISA.
Placental immunoexpression of Heme Oxygenase 1	At delivery within 24 until 38 weeks gestation.	Immunoexpression of Heme Oxygenase 1 in syncytiotrophoblasts, cytotrophoblasts, fetal endothelial cells, maternal vessels and decidual cells.

Secondary

Measure	Time frame	Description
Placenta histopathology examination	At delivery within 24 until 38 weeks gestation	Placenta will be examined histopathologically

Countries

Malaysia

Contacts

CONTACTRahana Abd Rahman, MOG (UKM)

drrahana@hctm.ukm.edu.my+60122719985

Outcome results